Chemistry:Ganitumab

Short description: Monoclonal antibody

Ganitumab
Monoclonal antibody
Type	Whole antibody
Source	Human
Target	IGF-1R
Clinical data
ATC code	none
Identifiers
CAS Number	905703-97-1^N
ChemSpider	none
UNII	CK1441RCZ8
KEGG	D09908^N
Chemical and physical data
Formula	C₆₄₇₂H₁₀₀₂₈N₁₇₂₈O₂₀₂₀S₄₂
Molar mass	145712.01 g·mol⁻¹
^NY (what is this?) (verify)

Ganitumab is a human monoclonal antibody against type 1 insulin-like growth factor receptor (IGF1R), designed for the treatment of cancers.^[1]^[2]

Ganitumab was developed by Amgen. A phase III clinical trial (for metastatic pancreatic cancer) was abandoned in August 2012.^[3]^[4]

References

↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Ganitumab". American MedicaAssociation. http://www.ama-assn.org/resources/doc/usan/ganitumab.pdf.
↑ "Ganitumab for the treatment of small-cell lung cancer". Expert Opinion on Investigational Drugs 23 (10): 1423–32. October 2014. doi:10.1517/13543784.2014.951434. PMID 25189625.
↑ "Amgen Pulls Cancer Drug". 10 Aug 2012. http://news.sciencemag.org/scienceinsider/2012/08/amgen-pulls-cancer-drug.html?ref=em.
↑ "Amgen (AMGN) Terminates Ganitumab Pancreatic Cancer Trial". 8 Aug 2012. http://www.istockanalyst.com/finance/story/5984012/amgen-amgn-terminates-ganitumab-pancreatic-cancer-trial.

Monoclonal antibodies for tumors

Tumor
("-t(u[m])-")

Human ("-tumu-")	Adecatumumab^§ Ascrinvacumab^§ Cixutumumab^§ Conatumumab^§ Daratumumab Drozitumab^§ Duligotumab^§ Dusigitumab^§ Enfortumab vedotin^† Enoticumab^§ Figitumumab^§ Ganitumab^† Glembatumumab vedotin^† Intetumumab^§ Ipilimumab Iratumumab^§ Istiratumab Icrucumab^§ Lexatumumab^§ Lucatumumab^§ Mapatumumab^§ Narnatumab^§ Necitumumab Nesvacumab^§ Nivolumab Ofatumumab Olaratumab^† Panitumumab Patritumab^§ Pembrolizumab Pritumumab^§ Radretumab^§ Ramucirumab Rilotumumab^† Robatumumab^§ Seribantumab^§ Tarextumab^§ Teprotumumab^† Tovetumab^§ Vantictumab^§ Votumumab^§ Zalutumumab^† "-melu-" (melanoma) Flanvotumab^§
Mouse ("-tumo-")	Altumomab pentetate Anatumomab mafenatox Arcitumomab Bectumomab Blinatumomab Detumomab Ibritumomab tiuxetan Lilotomab Minretumomab Mitumomab Moxetumomab pasudotox^† Naptumomab estafenatox Nofetumomab merpentan Pemtumomab^† Pintumomab Racotumomab Satumomab pendetide Solitomab Taplitumomab paptox Tenatumomab Tositumomab 3F8 "-govo-" (ovarian tumor) Abagovomab Igovomab Oregovomab "-pro-" (prostate tumor) Capromab pendetide "-colo-" (colonic tumor) Edrecolomab Nacolomab tafenatox
Chimeric ("-tuxi-")	Amatuximab^§ Bavituximab^§ Brentuximab vedotin Carotuximab^† Cetuximab Derlotuximab biotin^§ Dinutuximab Ensituximab^§ Futuximab^§ Girentuximab^† Indatuximab ravtansine^§ Isatuximab^† Loncastuximab tesirine Margetuximab^† Rituximab^# Siltuximab Ublituximab^† IMAB362 "-mexi-" (melanoma): Ecromeximab^§
Humanized ("-tuzu-")	Abituzumab^§ Alemtuzumab Bevacizumab Bivatuzumab mertansine^§ Brontictuzumab^§ Cantuzumab mertansine^§ Cantuzumab ravtansine^§ Cirmtuzumab Citatuzumab bogatox^§ Clivatuzumab tetraxetan Cofetuzumab pelidotin Dacetuzumab^§ Demcizumab^§ Dalotuzumab^§ Denintuzumab mafodotin^§ Elotuzumab Emactuzumab^§ Emibetuzumab^§ Enoblituzumab^§ Etaracizumab^§ Farletuzumab^§ Ficlatuzumab^§ Flotetuzumab^§ Gemtuzumab ozogamicin^‡ Imgatuzumab^§ Inotuzumab ozogamicin^† Labetuzumab^§ Lifastuzumab vedotin^§ Lintuzumab^§ Lorvotuzumab mertansine^§ Lumretuzumab^§ Matuzumab^§ Milatuzumab^§ Nimotuzumab^† Obinutuzumab Ocaratuzumab^§ Otlertuzumab^§ Onartuzumab^§ Oportuzumab monatox^† Parsatuzumab^§ Pertuzumab Pinatuzumab vedotin^§ Polatuzumab vedotin^† Rosmantuzumab Rovalpituzumab tesirine^† Sacituzumab govitecan^† Sibrotuzumab^§ Simtuzumab^§ Tacatuzumab tetraxetan^§ Tigatuzumab^§ Trastuzumab Tucotuzumab celmoleukin^§ Vandortuzumab vedotin^§ Vanucizumab^§ Veltuzumab^§ Vorsetuzumab mafodotin^§ CBR96-doxorubicin immunoconjugate PankoMab "-gozu-" (ovarian tumor) Sofituzumab vedotin^§
Rat/mouse hybrid ("-tumaxo-")	Catumaxomab Ertumaxomab^§
Chimeric + humanized ("-tuxizu-")	Depatuxizumab mafodotin^† Duvortuxizumab Ontuxizumab^§

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

0.00

(0 votes)

Original source: https://en.wikipedia.org/wiki/Ganitumab. Read more

Anonymous

Search

Chemistry:Ganitumab

Namespaces

More

Page actions

References

Navigation

Navigation

Help

Translate

Wiki tools

Wiki tools

Anonymous

Search

Chemistry:Ganitumab

References

Navigation

Wiki tools

Page tools

Other projects

Categories